Ambu A S Ord

Good morning, everyone, and welcome to the conference call for Ambush Q3 results. I'm Nikolai Thomson from the investor relations team. I'm here with our CEO, Britt Milbury-Jensen, and our CFO, Thomas Frank-Schmidt. Today's presentation can be found on our homepage, and there will be a Q&A session at the end of the call. And with that brief introduction, I'm very happy to hand over the word to our CEO, Britt Milbury-Jensen.

Good morning, everyone. Hope you're well. Nice to have you on the call for this Q3 results. For those of you who may not know me, I've spent over 20 years in healthcare in senior leadership positions at Novo Nordisk as CEO of Darko, Zeeland Pharma, and most recently as CEO of Atos Medical. Also, I've been on the board of directors of AMBU for almost three years.

Good morning, and also a warm welcome from my side as well. My background is I'm a chartered account by training, and I've for more than 20 years been both living and working abroad across Europe and Asia Pacific. Most of my career I've spent in the Roche Group in various financial leadership roles, and most recently as general manager of the Roche Farmer Switzerland business. I'm very excited to have my first quarterly earnings call today in my new role as CFO of Ambo.